Jun Ho Yi

9PUBLICATIONS
40CO-AUTHORS
Medical mycologyRegenerative medicine (incl. stem cells)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 11, 2026
Prospective Head-To-Head Comparison of a 10-Color Single-Tube Flow Cytometry and EuroFlow Next-Generation Flow in Multiple Myeloma Minimal Residual Disease.

|Feb 13, 2026
Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.

Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim

|Jan 04, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort.

Thomas G Martin, María-Victoria Mateos, Jun Ho Yi

|Aug 06, 2024
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.

Jun Ho Yi, Seok Jin Kim, Deok-Hwan Yang

|Feb 09, 2023
A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.

Jae-Cheol Jo, Youngwoo Jeon, DaJung Kim

|Feb 24, 2021
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.

Jun Ho Yi, Seok Jin Kim, Dok Hyun Yoon

Pageof 2

Frequent Collaborators

2 joint publications

Seung-Shin Lee

2 joint publications

Dae Sik Kim

2 joint publications

Ji Hyun Lee

2 joint publications

Deok-Hwan Yang